LENSAR Inc (LNSR) News

LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENSAR Reports Second Quarter 2023 Results and Provides Business Update

Increased ALLY® Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6 additional systems for installation as of...

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form 8-K - Current report

LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups

Private equity-owned ophthalmology group, EyeSouth Partners, adopts ALLY for each operating room within its Gainesville, Georgia and Boynton...

Securities Registration Statement (simplified Form) (s-3)

Table of Contents As filed with the Securities and Exchange Commission on June 26, 2023 Registration No. 333-   ...

Additional Proxy Soliciting Materials (definitive) (defa14a)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Proxy Statement (definitive) (def 14a)

Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...